A substrate specific functional polymorphism of human γ-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells
- 1 August 2004
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 14 (8) , 557-567
- https://doi.org/10.1097/01.fpc.0000114761.78957.7e
Abstract
We found a significant inverse relationship between γ-glutamyl hydrolase (GGH) activity and the accumulation of long-chain methotrexate polyglutamates (MTXPG4–7) in non-hyperdiploid B-lineage acute lymphoblastic leukaemia (ALL) cells after uniform treatment with high-dose methotrexate (HDMTX) (1 g/m2 i.v.). To identify genetic polymorphisms that alter the function of human GGH, we sequenced the GGH exons of genomic DNA from children with ALL, who had a 7.8-fold range of GGH activity in their ALL cells at diagnosis. A single nucleotide polymorphism (452C>T, T127I) was found among patients with low GGH activity, but not found in patients with high GGH activity. Computational modelling indicated that the T127I substitution alters the molecular surface conformation at the catalytic cleft-tail on GGH, which is predicted to alter binding affinity with long chain but not short-chain methotrexate polyglutamates. Enzyme kinetic analysis of heterologously expressed GGH revealed a significantly higher Km (2.7-fold) and lower catalytic efficiency (Vmax/Km reduced 67%) of the T127I variant compared to wild-type GGH using long-chain MTXPG5 as substrate, but not a significant change with short-chain MTXPG2. The 452C>T single nucleotide polymorphism (SNP) was also associated with lower GGH activity in hyperdiploid B-lineage and T lineage ALL cells. Caucasians [10.0%; 95% confidence interval (CI) 6.7–13.3%; n = 155] were found to have a significantly higher frequency of the Ile127 allele than African-Americans (4.4%; 95% CI 1.2–7.5%; n = 80) (P = 0.033). These studies demonstrate a substrate specific functional SNP (452C>T) in the human GGH gene that is associated with lower catalytic activity and higher accumulation of long-chain MTX-PG in leukaemia cells of patients treated with HDMTX.Keywords
This publication has 42 references indexed in Scilit:
- Resistance to antifolatesOncogene, 2003
- Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1998
- Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1998
- Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.Journal of Clinical Oncology, 1998
- Intrinsic and Acquired Resistance to Methotrexate in Acute LeukemiaNew England Journal of Medicine, 1996
- Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.Journal of Clinical Oncology, 1994
- Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.Journal of Clinical Oncology, 1994
- Karnofsky memorial lecture. Ode to methotrexate.Journal of Clinical Oncology, 1993
- Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update)Blood, 1991
- Polyglutamation of methotrexate. Is methotrexate a prodrug?Journal of Clinical Investigation, 1985